Conjugate Vaccines Market Research Report - Forecast till 2030

Conjugate Vaccines Market Research Report, By Type (Haemophilus B, Monovalent, Multivalent, And Others), Indication (Influenza, Pneumococcal, Meningococcal, And Others), End Users (Pediatrics And Adults) - Forecast Till 2030

ID: MRFR/Pharma/2981-HCR | 115 Pages | Published By Rahul Gotadki on March 2023         

Table of Contents

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6. Global Conjugates Vaccines Market, by Type

6.1 Haemophilus B

6.2 Monovalent

6.3 Multivalent

6.4 Others

7. Global Conjugates Vaccines Market, by Indication

7.1 Influenza

7.2 Pneumococcal

7.3 Meningococcal

7.4 Others

8. Global Conjugates Vaccines Market, by End User

8.1 Pediatrics

8.2 Adults

9. Global Conjugates Vaccines Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 UK

9.3.1.3 France

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of Middle East & Africa

10 Competitive Landscape

10.1 Cost of Products

10.2 Production Capacity of Major Players

11 Company Profile

11.1 GlaxoSmithKline plc.

11.1.1 Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Updates

11.1.4 Key Developments

11.2 Merck & Co., Inc.

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Updates

11.2.4 Key Developments

11.3 Fablife

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Updates

11.3.4 Key Development

11.4 Pfizer Inc

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Updates

11.4.4 Key Development

11.5 SutroVax Inc

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Updates

11.5.4 Key Developments

11.6 Taj Pharmaceuticals Limited

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Updates

11.6.4 Key Developments

11.7 Sanofi Pasteur SA

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Updates

11.7.4 Key Developments

11.8 Sinovac Biotech Ltd

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Updates

11.8.4 Key Developments

11.9 Bavarian Nordic

11.9.1 Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financial Updates

11.9.4 Key Developments

11.9 Others

12 Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Conjugates Vaccines Industry

13 Appendix